A research collaboration dating from 2015 has yielded a licensing agreement for Argenx NV of Belgium. The deal involves an antibody targeted ApoC3, a protein involved in dyslipidemia, a disorder caused by an abnormal amount of lipids in the blood. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
